HTS/HCS Discovery Arm
The mission of the University of Colorado Anschutz Medical Campus (CU AMC) Drug Discovery and Development Shared Resource (D3SR) is to provide expertise and infrastructure to facilitate drug discovery at different stages of the development pipeline, including assay development and validation, high-throughput screening (HTS) and image-based high-content screening (HCS) discovery, hit-to-lead validation and optimization, and in vitro and in vivo pharmacology including pharmacokinetics (PK) and pharmacodynamics (PD) as well as toxicology.
To accomplish our mission the D3SR facility consists of two arms: (1) drug discovery and hit-to-lead drug development, and (2) in vivo pharmacology. Arm 1 of the D3SR is directed by Dan LaBarbera, PhD, CU AMC Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS); and Arm 2 is directed by Dan Gustafson, PhD, located at Colorado State University (CSU). The D3SR is the main research infrastructure formally affiliated with a new CU AMC Center for Drug Discovery (CDD) housed in the SSPPS, and the University of Colorado Cancer Center (CUCC). The D3SR supports drug discovery and development research for both the CDD and the CUCC affiliated members. In addition, the D3SR facility is an available resource for all academic, government, and industry researchers or institutions interested in drug discovery at CU AMC, in Colorado, throughout the United States, and Internationally.
This site is specific for researchers interested in utilizing the D3SR Arm 1 HTS/HCS Discovery. For those interested in utilizing the Pharmacology Arm 2 please visit the website link below. The D3SR Arm 1 specializes in HTS/HCS probe and drug discovery using cellular and biochemical systems. We also specialize in three-dimensional (3D) HTS/HCS and analysis of organoids and tumor organoids (cell line or patient derived). This facility is newly renovated and features a new state-of-the-art custom robotic automation platform (the Explorer G3) that integrates new HTS/HCS instrumentation and equipment from PerkinElmer and other leading vendors.
Acknowledging the D3SR in Publications
Below is a recommended acknowledgment for all D3SR user projects that have progressed to preparing manuscripts being considered for publication in peer-review journals or other media outlets.
"The authors would like to thank the Drug Discovery and Development Shared Resource (D3SR) for their contribution to this work. TheD3SR is supported in part by the CU Cancer Center, an NIH NCI designated cancer center (P30CA046934); and the CU AMC Center for Drug Discovery, which was established from a generous gift from the ALSAM Foundation and through CU AMC institutional support."
Expectations Regarding Publications and Intellectual Property
Given the complexity, scientific and technological input by the D3SR for the successful completion of drug discovery projects, it is our expectation that all contributors will be included as authors for any publications that will likely arise from the D3SR. We are happy and willing to contribute to the production and writing of any manuscripts related to D3SR projects. Likewise, if intellectual property (IP) is developed as a result of D3SR contributions, all contributors should be included in any technology transfer IP disclosures.
HTS/HCS Discovery Arm
12850 E Montview Blvd, V20-2210
Aurora, CO 80045